We serve Chemical Name:2-(ethoxymethyl)pyrazine CAS:65504-94-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(ethoxymethyl)pyrazine
CAS.NO:65504-94-1
Synonyms:Methylethoxypyrazine;2-Ethoxymethylpyrazine;EINECS 265-794-5;Pyrazine,2-ethoxymethyl
Molecular Formula:C7H10N2O
Molecular Weight:138.16700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:190.6ºC at 760 mmHg
Density:1.038 g/mL at 25ºC(lit.)
Index of Refraction:n20/D 1.494(lit.)
PSA:35.01000
Exact Mass:138.07900
LogP:1.01310
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like Methylethoxypyrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrazine,2-ethoxymethyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methylethoxypyrazine Use and application,2-Ethoxymethylpyrazine technical grade,usp/ep/jp grade.
Related News: The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 2-(ethoxymethyl)pyrazine manufacturer With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near 2-(ethoxymethyl)pyrazine supplier Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2-(ethoxymethyl)pyrazine vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 2-(ethoxymethyl)pyrazine factory When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau.
